Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for "Diabesity".

Peptidic agonists of the glucagon-like peptide-1 receptor (GLP-1R) have gained a prominent role in the therapy of type-2 diabetes and are being considered for reducing food intake in obesity. Potential advantages of small molecules acting as positive allosteric modulators (PAMs) of GLP-1R, including oral administration and reduced unwanted effects, could improve the utility of this class of drugs. Here, we describe the discovery of compound 9 (4-{[1-({3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}methyl)piperidin-3-yl]methyl}morpholine, V-0219) that exhibits enhanced efficacy of GLP-1R stimulation, subnanomolar potency in the potentiation of insulin secretion, and no significant off-target activities. The identified GLP-1R PAM shows a remarkable in vivo activity, reducing food intake and improving glucose handling in normal and diabetic rodents. Enantioselective synthesis revealed oral efficacy for (S)-9 in animal models. Compound 9 behavior bolsters the interest of a small-molecule PAM of GLP-1R as a promising therapeutic approach for the increasingly prevalent obesity-associated diabetes.

A Positive Allosteric Modulator of the Serotonin 5-HT2C Receptor for Obesity.

The 5-HT2CR agonist lorcaserin, clinically approved for the treatment of obesity, causes important side effects mainly related to subtype selectivity. In the search for 5-HT2CR allosteric modulators as safer antiobesity drugs, a chemical library from Vivia Biotech was screened using ExviTech platform. Structural modifications of identified hit VA240 in synthesized analogues 6-41 afforded compound 11 (N-[(1-benzyl-1H-indol-3-yl)methyl]pyridin-3-amine, VA012), which exhibited dose-dependent enhancement of serotonin efficacy, no significant off-target activities, and low binding competition with serotonin or other orthosteric ligands. PAM 11 was very active in feeding inhibition in rodents, an effect that was not related to the activation of 5-HT2AR. A combination of 11 with the SSRI sertraline increased the anorectic effect. Subchronic administration of 11 reduced food intake and body weight gain without causing CNS-related malaise. The behavior of compound 11 identified in this work supports the interest of a serotonin 5-HT2CR PAM as a promising therapeutic approach for obesity.

RCM for the construction of novel steroid-like polycyclic systems. 1. Studies on the synthesis of a PreD3-D3 transition state analogue.

Natural and nonnatural polycyclic systems containing eight-membered carbocycles constitute a large class of compounds of importance in organic chemistry, biology, and medicine. Here we describe a new strategy by which complex polycyclic steroid-like systems can be constructed on the steroid CD framework, by a combination of RCM and Heck cyclizations. The method is exemplified by its application to the stereoselective synthesis of 6-8-6 fused carbocyclic systems that mimic the putative transition structure of the isomerization of previtamin D3 to vitamin D3.

Tandem RCM of dienynes for the construction of taxol-type carbocyclic systems.

[reaction: see text] Tandem ring-closing metathesis of hydrindanone dienynes allows access to taxosteroids, a new class of compounds that combine the [5.3.1] carbocyclic system of taxanes with rings C and D of the steroid skeleton.

Toward an analogue of the transition state of preD3-D3 isomerization: stereoselective synthesis of linearly fused 6-8-6 carbocyclic systems.

[reaction: see text] A stereoselective synthesis of 6-8-6 fused carbocyclic systems based on enol alkylation, ketone allylation, RCM, and Heck cyclization was developed to obtain compounds with a carbon framework that mimics the putative transition structure of the isomerization of previtamin D3 to vitamin D3.